Spike Protein News and Research

RSS

“Sybodies” protect against SARS-CoV-2 in hamster model

Researchers in China, The Netherlands, France, and Switzerland have identified synthetic nanobodies or “sybodies” that exhibit potent neutralizing activity against severe acute respiratory syndrome coronavirus (SARS-CoV-2) – the agent responsible for the ongoing coronavirus disease 2019 (COVID-19) pandemic.

3 Aug 2021

Study suggests second Pfizer-BioNTech vaccine shot may not be needed after previous SARS-CoV-2 infection

Researchers in Austria have conducted a study showing that individuals previously infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibit a significantly more pronounced antibody response to one dose of Pfizer-BioNTech’s coronavirus disease 2019 (COVID-19) vaccine than previously uninfected individuals.

3 Aug 2021

SARS-CoV-2 Delta and Delta AY.1 variant show similar Covaxin-induced neutralization

A new study from India suggests that the Indian-made Covaxin whole-virus inactivated vaccine against the SARS-CoV-2 retains significant efficacy against the newer delta variants of the virus.

3 Aug 2021

Study shows efficacy of Pfizer-BioNTech and Moderna vaccines against SARS-CoV-2 delta variant

Researchers in Singapore have conducted a study showing that the messenger RNA- (mRNA) based coronavirus disease 2019 (COVID-19) vaccines developed by Pfizer-BioNTech and Moderna are highly effective at protecting against symptomatic and severe disease following infection with the rapidly spreading B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

2 Aug 2021

Pfizer moves towards an oral anti-COVID-19 therapy

Researchers in the United States have described a novel antiviral agent against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) currently being evaluated in clinical trials as a treatment for coronavirus disease 2019 (COVID-19).

2 Aug 2021

Scientists develop a potent peptide inhibitor of SARS-CoV-2 in vitro

In a recently published article in the journal Drugs in R&D, scientists have described the development and validation of a 13-amino acid peptide inhibitor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

2 Aug 2021

SARS-CoV-2 Q493R protein mutation shows resistance to monoclonal antibodies

The Centers for Disease Control and Prevention (CDC) issued a letter detailing a case of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an immunocompromised patient who did not respond well to monoclonal antibody treatment. The resistance to treatment stemmed from an escape mutation on the spike protein known as Q4923R.

2 Aug 2021

Antibody responses following SARS-CoV-2 infection more potent than vaccine-elicited ones

Researchers in the United States have conducted a study showing the difference in antibody evolution following vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) between people who have not previously been infected with the virus and those who have.

1 Aug 2021

Study looks at potent phytocompounds from Himalayan herbs to treat COVID-19

Considering the antiviral activity of medicinal herbs, a new study published in the journal Current Pharmacology Reports focuses on the identification of potent phytochemicals from Himalayan herbs, namely, Rheum emodi, Thymus serpyllum, and Artemisia annua, for the treatment of COVID-19.

1 Aug 2021

Prior SARS-CoV-2 infection enhances Johnson and Johnson Ad26.COV2.S vaccine immunogenicity

A new study reports that the Johnson and Johnson vaccine against COVID-19 shows enhanced efficacy when administered to individuals with pre-existing antibodies.

30 Jul 2021

Scientists suspect Lambda SARS-CoV-2 variant most dangerous

A new study published on the bioRxiv* preprint server used molecular phylogenetic analysis to study the evolutionary trait of the Lambda variant.

30 Jul 2021

SARS-CoV-2 interacts with sialic acid cell surface glycans

In a paper recently uploaded to the journal Frontiers in Chemistry by Li et al. (July 22nd, 2021) the interaction between the SARS-CoV-2 spike protein and N-acetylneuraminic acid (NANA), the most commonly found sialic acid in humans, is investigated, finding that the molecule may act as a secondary or supplementary receptor to the virus.

30 Jul 2021

Phase 1/2 trial results for Nanocovax, protein subunit SARS-CoV-2 vaccine from Vietnam

Nanocovax is a protein subunit vaccine that contains the full-length spike stabilized by the addition of two prolines

29 Jul 2021

Study explains how SARS-CoV-2 variants differ in binding to ACE2 receptor

The current study explored ACE2-RBD interactions with four VoCs including the Alpha, Beta, Gamma, and Delta variants.

29 Jul 2021

Study reveals cellular basis of antigen-specific response to Pfizer-BioNTech’s COVID-19 vaccine

Researchers in the United States have provided important insights into the antigen-specific cellular response and evolving humoral (antibody) response to messenger RNA- (mRNA) based vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

29 Jul 2021

Spike Protein News and Research

“Sybodies” protect against SARS-CoV-2 in hamster model

Study suggests second Pfizer-BioNTech vaccine shot may not be needed after previous SARS-CoV-2 infection

SARS-CoV-2 Delta and Delta AY.1 variant show similar Covaxin-induced neutralization

Study shows efficacy of Pfizer-BioNTech and Moderna vaccines against SARS-CoV-2 delta variant

Pfizer moves towards an oral anti-COVID-19 therapy

Scientists develop a potent peptide inhibitor of SARS-CoV-2 in vitro

SARS-CoV-2 Q493R protein mutation shows resistance to monoclonal antibodies

Antibody responses following SARS-CoV-2 infection more potent than vaccine-elicited ones

Study looks at potent phytocompounds from Himalayan herbs to treat COVID-19

Prior SARS-CoV-2 infection enhances Johnson and Johnson Ad26.COV2.S vaccine immunogenicity

Scientists suspect Lambda SARS-CoV-2 variant most dangerous

SARS-CoV-2 interacts with sialic acid cell surface glycans

Phase 1/2 trial results for Nanocovax, protein subunit SARS-CoV-2 vaccine from Vietnam

Study explains how SARS-CoV-2 variants differ in binding to ACE2 receptor

Study reveals cellular basis of antigen-specific response to Pfizer-BioNTech’s COVID-19 vaccine

Mass spectrometry used to develop N-glycosylation profiles for SARS-CoV-2 D614G

Mini-antibodies efficiently block SARS-CoV-2 virus

Unraveling the mysterious mutations that make delta the most transmissible covid virus yet

Immunity to SARS-CoV-2 in renal transplant and dialysis patients using Pfizer/BioNTech and Moderna vaccines

SARS-CoV-2 spike-specific antibodies induced in breast milk by COVID-19 vaccines

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News